Edition:
India

Allena Pharmaceuticals Inc (ALNA.OQ)

ALNA.OQ on NASDAQ Stock Exchange Global Select Market

4.82USD
17 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.82
Open
$4.92
Day's High
$4.97
Day's Low
$4.81
Volume
11,683
Avg. Vol
33,683
52-wk High
$12.31
52-wk Low
$3.92

Latest Key Developments (Source: Significant Developments)

Allena Pharmaceuticals Reports Q1 Loss Per Share Of $0.55
Wednesday, 8 May 2019 

May 8 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.55.Q1 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.ALL CLINICAL PROGRAMS PROGRESSING ON TRACK;.ALLENA PHARMACEUTICALS-SEES EXISTING CASH & CASH EQUIVALENTS TO BE SUFFICIENT TO FUND OPERATING EXPENSES & CAPITAL REQUIREMENTS THROUGH AT LEAST 1H20.  Full Article

Allena Pharmaceuticals Qtrly Net Loss Per Share $0.46
Thursday, 7 Mar 2019 

March 7 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.QTRLY NET LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE VIEW $-0.51 -- REFINITIV IBES DATA.PHASE 3 URIROX-1 AND URIROX-2 TRIALS ONGOING; URIROX-1 TOPLINE DATA EXPECTED IN SECOND HALF OF 2019.LOUIS BRENNER, M.D. APPOINTED CHIEF EXECUTIVE OFFICER.EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA IN SECOND HALF OF 2019 FOR ALLN-346.EXPECTS TO INITIATE FIRST CLINICAL TRIAL IN FIRST HALF OF 2020 FOR ALLN-346.  Full Article

Allena Pharmaceuticals Completes Animal Proof-Of-Concept Study For ALLN-346
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS COMPLETES ANIMAL PROOF-OF-CONCEPT STUDY FOR ALLN-346, LEAD PRODUCT CANDIDATE FOR HYPERURICEMIA IN THE SETTING OF ADVANCED CHRONIC KIDNEY DISEASE.ALLENA PHARMACEUTICALS INC - EXPECTS TO FILE AN IND WITH U.S. FOOD AND DRUG ADMINISTRATION IN FIRST HALF OF 2019.  Full Article

Allena Pharmaceuticals Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $0.48
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.‍QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.48.ALLENA PHARMA- EXPECTS EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS SUFFICIENT TO FUND OPERATING EXPENSES, CAPITAL REQUIREMENTS INTO 2020.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2017 WAS $94.5 MILLION.  Full Article

Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA.ALLENA PHARMACEUTICALS INC - ‍TOPLINE DATA FROM PHASE 3 TRIAL FOR ALLN-177 EXPECTED IN SECOND HALF OF 2019​.ALLENA PHARMACEUTICALS INC - ‍EXPECTS TO INITIATE URIROX-2 IN SECOND HALF OF 2018, CONSISTENT WITH PRIOR GUIDANCE​.ALLENA - ‍INITIATION OF URIROX-1 TRIAL FOLLOWS MULTIPLE INTERACTIONS WITH FDA AFTER WHICH FDA CONFIRMED IT HAD NO COMMENTS ON PROTOCOL​.ALLENA PHARMACEUTICALS INC - ‍CONTINUES TO ENGAGE WITH FDA TO FINALIZE DESIGN OF URIROX-2​.ALLENA - ENGAGING FDA TO DISCUSS PURSUING ACCELERATED APPROVAL PATHWAY FOR PLANNED BLA SUBMISSION FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA​.ALLENA - ‍BELIEVES PHASE 3 PROGRAM, IF SUCCESSFUL, COULD BE ELIGIBLE FOR MAA VIA CONDITIONAL APPROVAL PATHWAY​.  Full Article

Allena Pharma Reports Q3 Loss Per Share $3.49
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Allena Pharmaceuticals Inc ::ALLENA PHARMACEUTICALS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $3.49.Q3 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

HBM BioCapital II reports 7.94 pct passive stake in Allena Pharma
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Allena Pharmaceuticals Inc :HBM BioCapital II LP reports 7.94 percent passive stake in Allena Pharmaceuticals Inc as of November 6, 2017 - SEC filing‍​.  Full Article

Allena Pharmaceuticals shares open 14.3 pct below IPO price in debut
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - :Allena Pharmaceuticals shares open at $12 in debut on the NASDAQ versus IPO price of $14/shr‍​.  Full Article

Allena Pharmaceuticals prices IPO of 5.3 mln shares at $14 per share
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Allena Pharmaceuticals Inc :Allena pharmaceuticals, Inc. Announces pricing of initial public offering.Says priced its initial public offering of 5.3 million shares of common stock at a public offering price of $14.00 per share​.  Full Article

Allena Pharmaceuticals sees IPO price range of $14-$16/shr
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Allena Pharmaceuticals Inc :Allena pharmaceuticals Inc sees IPO of up to 5.33 million shares‍​ of common stock to be priced between $14 and $16 per share - SEC filing‍​.  Full Article